Contents

Search


hemangioendothelioma

Epidemiology: - rare malignant tumor - sffects fewer than 300 patients per year in the United States - accounts for ~1% of all vascular neoplasms Pathology: - bone involvement - tumors express a wide variety of ligands & receptors for VEGF - ~15% of patients with epithelioid hemangioendothelioma die of the disease - tissue biopsy Microscopic pathology: - immunohistochemical staining - tumor cells positive for vascular endothelial markers CD31 & FLI1 - staining for CD117 may show scattered mast cells Genetics: - chromosomal translocation involving chromosome 1 & chromosome 3 Radiology: - computed tomography or magnetic resonance imaging Management: - treted as low-to-intermediate-grade angiosarcoma - bevacizumab of benefit in a minority of patients - monotherapy with sunitinib, thalidomide, lenalidomide, or IFN-alpha with reported benefits - gemcitabine, carboplatin-etoposide, & liposomal doxorubicin of reported benefit - pallitative radiation therapy for bone pain

Interactions

disease interactions

General

vascular tissue neoplasm; angioma

References

  1. Choy E, Attar EC, Oh KS, Huang AJ, Kerr DA. Case 33-2014 - A 60-Year-Old Man with Bone Pain. N Engl J Med 2014; 371:1630-1640. October 23, 2014 PMID: 25337753 http://www.nejm.org/doi/full/10.1056/NEJMcpc1310000